- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Patent holdings for IPC class A61P 29/00
Total number of patents in this class: 21221
10-year publication summary
|
549
|
925
|
1142
|
1224
|
1337
|
1505
|
1554
|
1444
|
1345
|
175
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7881 |
204 |
| Bristol-myers Squibb Company | 4809 |
181 |
| Boehringer Ingelheim International GmbH | 4587 |
180 |
| Janssen Pharmaceutica N.V. | 3322 |
148 |
| Takeda Pharmaceutical Company Limited | 2712 |
137 |
| Novartis AG | 10481 |
118 |
| The Regents of the University of California | 20366 |
107 |
| Allergan, Inc. | 2265 |
98 |
| Centre National de La Recherche Scientifique | 10802 |
96 |
| AstraZeneca AB | 2816 |
95 |
| Genentech, Inc. | 4038 |
87 |
| Daiichi Sankyo Company, Limited | 1876 |
86 |
| Hoffmann-La Roche Inc. | 3603 |
85 |
| Grünenthal GmbH | 544 |
79 |
| Amgen Inc. | 4290 |
74 |
| Merck Patent GmbH | 5726 |
73 |
| Gilead Sciences, Inc. | 2136 |
73 |
| Vertex Pharmaceuticals Incorporated | 1623 |
69 |
| Glaxo Group Limited | 4207 |
68 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 853 |
68 |
| Other owners | 19095 |